MNPR: Monopar Therapeutics Inc.
Performance
MNPR -8.89%
Watchlist
Select an item
Summary
MNPR at a glance
MNPR returned -8.89% over the past year and +23.74% a year over five years. Its worst drop in that year was -46.48%, smaller than 28% of stocks on Redstone, and its Sharpe ratio of 0.11 beats 31% of stocks on Redstone. It pays no dividends.
Current Drawdown
-40.45%
Rolling Volatility
60.80%
Actions
Metrics
Risk Indicators
Alpha-6.17%
Beta1.33x
Sharpe0.11
Sortino0.17
Omega1.02
Calmar-0.19
Martin0.24
Profile
About MNPR
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine.
- Sector
- Health Care
- Industry
- Pharmaceutical Preparations
- Market cap
- $495M
- Listed
- Dec 2019
- Employees
- 22
- Headquarters
- Wilmette, IL
- Website
- monopartx.com
Comparisons